Sedivention GmbH

Germany - Straßlach-Dingharting

• 03/12/2024
• Pre-Seed
• $839,204

Sedivention develops a break-through, widely applicable, device for interventional obesity therapy. Hunger is transmitted from the stomach to the brain by the gastric trunks of the vagal nerve. Sedivention is developing a cryo-balloon freezing the gastric branches of the vagal nerve from inside the stomach, in a procedure comparable to gastroscopy. The ambulatory intervention takes approximately 20 min. The costs of the intervention are far below costs of bariatric surgery without surgical morbidity and complications. In brief: Sedivention develops the first long-term effective, scalable therapy for obesity: No scars, no pain, no surgical complications, no access barriers at an affordable price. Obesity causes over 400.000 deaths yearly in the US alone and costs of more than 2.0 trillion $US worldwide. According to the WHO obesity Atlas 2022, there will be 1 billion obese persons worldwide in 2030.

Related People

Ute Dr. med. NollertFounder

Germany - Straßlach-Dingharting, Bavaria

I am a consultant anesthesiologist, affiliated to the Sana Klinik München. In 2021, I founded sedivention, a medtech company, that develops a device for interventional obesity therapy.

LinkedIn https://www.linkedin.com/in/ute-dr-med-nollert-93922b22b/